title: Differential regulation of mouse equilibrative nucleoside transporter 1 (mENT1) splice variants by protein kinase CK2.
abstract: Nucleosides are accumulated by cells via a family of equilibrative transport proteins (ENTs). An alternative splice variant of the most common subtype of mouse ENT (ENT1) has been identified which is missing a protein kinase CK2 (casein kinase 2) consensus site (Ser(254)) in the central intracellular loop of the protein. We hypothesized that this variant (mENT1a) would be less susceptible to modulation by CK2-mediated phosphorylation compared to the variant containing the serine at position 254 (mENT1b). Each splice variant was transfected into nucleoside transporter deficient PK15 cells, and stable transfectants assessed for their ability to bind the ENT1-selective probe [(3)H]nitrobenzylthioinosine (NBMPR) and to mediate the cellular uptake of [(3)H]2-chloroadenosine, with or without treatment with the CK2 selective inhibitor, 4,5,6,7-tetrabromobenzotriazole (TBB). mENT1a had a higher affinity for NBMPR relative to mENT1b - measured both directly by the binding of [(3)H]NBMPR, and indirectly via inhibition of [(3)H]2-chloroadenosine influx by NBMPR. Furthermore, incubation of mENT1b-expressing cells with 10 microM TBB for 48 h decreased both the K(D) and B(max) of [(3)H]NBMPR binding, as well as the V(max) of 2-chloroadenosine uptake, whereas similar treatment of mENT1a-expressing cells with TBB had no effect. PK15 cells transfected with hENT1, which has Ser(254), was similar to mENT1b in its response to TBB. In conclusion, inhibition of CK2 activity, or deletion of Ser(254) from mENT1, enhances transporter affinity for the inhibitor, NBMPR, and reduces the number of ENT1 proteins functioning at the level of the plasma membrane.
authors.affiliation: Department of Physiology & Pharmacology, Schulich School of Medicine and Dentistry, University of Western Ontario, London, Ontario, Canada.
authors.forename: Derek B J
authors.initials: DB
authors.lastname: Bone
authors.forename: Kevin R
authors.initials: KR
authors.lastname: Robillard
authors.forename: Meaghan
authors.initials: M
authors.lastname: Stolk
authors.forename: James R
authors.initials: JR
authors.lastname: Hammond
mesh_terms: D015762:2-Chloroadenosine / Q000493:pharmacokinetics; D000818:Animals; D047390:Casein Kinase II / Q000037:antagonists & inhibitors / Q000502:physiology*; D002460:Cell Line; D004791:Enzyme Inhibitors / Q000494:pharmacology; D033721:Equilibrative Nucleoside Transporter 1; D007700:Kinetics; D051379:Mice; D033703:Nucleoside Transport Proteins / Q000032:analysis / Q000235:genetics / Q000378:metabolism*; D011485:Protein Binding; D020033:Protein Isoforms / Q000378:metabolism; D012694:Serine; D014162:Transfection
chemical_list: D004791:Enzyme Inhibitors; D033721:Equilibrative Nucleoside Transporter 1; D033703:Nucleoside Transport Proteins; D020033:Protein Isoforms; C498476:SLC29A1 protein, mouse; D015762:2-Chloroadenosine; D012694:Serine; D047390:Casein Kinase II